Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 is an effective inhibitor of inhaled p38 MAPK. PF-03715455 displays some selectivity for p38α over p38β (respective IC50: 0.88 and 23 nM). PF-03715455 has the potential for the treatment of COPD.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約10-14 週間 | ¥ 624,500 |
50 mg | 約10-14 週間 | ¥ 822,000 |
100 mg | 約10-14 週間 | ¥ 1,124,500 |
説明 | PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 is an effective inhibitor of inhaled p38 MAPK. PF-03715455 displays some selectivity for p38α over p38β (respective IC50: 0.88 and 23 nM). PF-03715455 has the potential for the treatment of COPD. |
ターゲット&IC50 | p38β:23 nM, p38α:0.88 nM |
In vitro | PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6. It also is an effective inhibitor of CYP's 2C9 and CYP3A4[2]. |
In vivo | PF-03715455 treatment displays that the Vss is 0.19 L/kg and T1/2 is 1 hour [2]. |
分子量 | 700.27 |
分子式 | C35H34ClN7O3S2 |
CAS No. | 1056164-52-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PF-03715455 1056164-52-3 MAPK p38 MAPK PF03715455 PF 03715455 Inhibitor inhibitor inhibit